b-lactam Antibiotics and Gastrointestinal Colonization with Vancomycin-Resistant Enterococci
|
|
- Muriel White
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE b-lactam Antibiotics and Gastrointestinal Colonization with Vancomycin-Resistant Enterococci Louis B. Rice, 1,2,3 Rebecca Hutton-Thomas, 1 Viera Lakticova, 2 Marion S. Helfand, 1 and Curtis J. Donskey 1 1 Medical and Research Services, Louis Stokes Cleveland VA Medical Center, 2 The Cleveland Veterans Affairs Research and Education Foundation, and 3 Department of Medicine, Case Western Reserve University, Cleveland, Ohio We studied the effect of different subcutaneously administered b-lactam antibiotics on the establishment of gastrointestinal colonization by vancomycin-resistant Enterococcus faecium C68 in a mouse model. Aztreonam, cefazolin, cefepime, and, to a lesser extent, ceftazidime, which neither have significant antienterococcal activity nor are secreted into human bile at high concentrations, did not promote significant vancomycin-resistant enterococci (VRE) colonization. Piperacillin-tazobactam, which has antienterococcal activity and is secreted in human bile at high concentrations, inhibited colonization after limited exposure to the inoculum but was associated with progressively increased VRE colony counts in stool samples after repeated exposure to the VRE inoculum. Ceftriaxone and cefotetan, which lack antienterococcal activity but are secreted into human bile at high concentrations, were associated with rapid and high-level colonization. These data suggest that the risk of VRE colonization varies during exposure to different b-lactam antimicrobial agents and that the risk is related to biliary concentration and antienterococcal activity of the specific b-lactam. Despite never having been described before the late 1980s, enterococci expressing resistance to the glycopeptide antibiotic vancomycin have spread widely and have grown in clinical importance over the past decade [1, 2]. Data from the Center for Disease Control s National Nosocomial Infection Surveillance System indicate that 25% of enterococcal strains isolated from documented infections occurring in patients from intensive care units are now resistant to vancomycin [3]. Moreover, the vast majority of vancomycin-resistant enterococci (VRE) are Enterococcus faecium that also express high levels of resistance to ampicillin [1, 2]. As a result, our 2 most reliable antienterococcal drugs are Received 6 May 2003; accepted 7 September 2003; electronically published 1 March Financial support: Elan. Potential conflicts of interest: L.B.R. is a consultant for Elan, Wyeth-Ayerst, Merck, Pharmacia, Intermune, Basilea, Essential Therapies, Cubist, Shire, and Genome Therapeutics; belongs to the speakers bureaus of Elan, Wyeth-Ayerst, and Merck; and has received grant support from Elan, Wyeth-Ayerst, andintermune. C.J.D. is a consultant for and has received grant support from Ortho-McNeil and IPSAT Therapies. Reprints or correspondence: Dr. Louis B. Rice, Medical Service 111(W), Louis Stokes Cleveland VA Medical Center, East Blvd., Cleveland, OH (louis.rice@med.va.gov). The Journal of Infectious Diseases 2004; 189: This article is in the public domain, and no copyright is claimed /2004/ inactive against these strains. This inactivity results in the use of less-effective regimens or, more recently, in the use of newer antienterococcal agents, such as linezolid or quinupristin-dalfopristin. Although both of these newer agents have proved to be effective in treating VRE infections, baseline rates of reduced susceptibility to quinupristin-dalfopristin have been relatively high, and emergence of resistance to linezolid during treatment is increasingly being documented [4, 5]. Substantial data now support the concept that gastrointestinal colonization with VRE commonly precedes VRE infection [6]. VRE infections, in turn, occur most commonly in patients with immunocompromising conditions who have been treated with multiple antimicrobial agents during prolonged hospitalizations [5, 7]. Although, initially, there was debate about whether VRE were truly pathogenic in humans, 2 recent studies have demonstrated a clear association between infection with VRE and mortality, compared with patients infected with vancomycin-susceptible enterococci [5, 7]. Moreover, at least 2 potential virulence determinants, enterococcal surface protein [8] and hyaluronidase [9], have now been described to occur in VRE and may increase their pathogenicity. Understanding the factors that promote colonization and infection with VRE has, therefore, assumed considerable importance. b-lactam Antibiotics and VRE Colonization JID 2004:189 (15 March) 1113
2 Receipt of antimicrobial treatment has emerged as a critical factor for promoting gastrointestinal VRE colonization in hospitalized patients. Although vancomycin was initially presumed to be the primary risk factor for acquisition of VRE, careful clinical studies soon identified a variety of antimicrobial exposures as risk factors for VRE colonization. The most prominent among these has been exposure to cephalosporins (in particular third-generation cephalosporins) and antimicrobial agents with potent activity against anaerobic bacteria [10, 11]. In an animal study designed to investigate these associations, Donskey et al. [12] used a mouse model of VRE colonization to show that potent activity against anaerobic bacteria was a common characteristic of antibiotics associated with persistence of high-level VRE colonization in mouse feces. Contrary to the initial hypotheses of these studies, the fourth-generation cephalosporin cefepime did not promote persistence of VRE. The third-generation cephalosporin ceftriaxone promoted persistence, to some extent, in these studies, but not to the degree provided by those agents with very potent activity against anaerobic bacteria. Piperacillin-tazobactam, which has not been frequently associated with VRE colonization or infection in clinical studies, was found to promote persistence of VRE colonization in these studies, presumably because of its high levels of gastrointestinal secretion and potency against anaerobic bacteria. Donskey et al. [13] extended these studies to humans, documenting a strong tendency for increased quantities of VRE to be present in stool samples from colonized patients exposed to potent antianaerobic regimens. In an effort to further understand the association between exposure to antimicrobials and VRE colonization, Donskey et al. [14] established a second model of VRE colonization, in which the ability to promote the establishment of colonization (rather than persistence in animals already colonized) was tested. In these studies, they found that exposure to piperacillintazobactam was protective against establishment of VRE colonization, whereas exposure to either ceftriaxone or ticarcillinclavulanic acid promoted rapid establishment of high-level VRE colonization. They concluded that the modest activity of piperacillin-tazobactam against ampicillin-resistant E. faecium (MIC, mg/ml), combined with substantial biliary secretion of piperacillin ( mg/ml in bile in human studies [15]) was sufficient to suppress growth of VRE in the upper gastrointestinal tract and to forestall high-level colonization. Ceftriaxone, on the other hand, was so devoid of activity against ampicillin-resistant E. faecium (MIC, 110,000 mg/ml [16]) that even the very high concentrations of this antibiotic that are achievable in human bile ( 5000 mg/ml [17]) were insufficient to inhibit growth in the upper gastrointestinal tract, thereby favoring establishment of colonic VRE colonization. Ticarcillinclavulanic acid also promoted establishment of VRE colonization in these studies, presumably because of its very poor activity against ampicillin-resistant E. faecium (MIC, 10,000 mg/ml [16]), combined with its potent activity against anaerobic bacteria. Taken together, these data suggest that the likelihood that a particular b-lactam antibiotic will promote initial VRE colonization will depend on several factors, including the intrinsic activity against VRE and the potency of the agent against anaerobic bacteria. Ceftriaxone and piperacillin-tazobactam are both significantly concentrated in the bile. Because of this concentration, it is conceivable that ceftriaxone is particularly likely to select for VRE colonization and that other cephalosporins without this characteristic but with weak antianaerobic activity may be less likely to select for colonization. To further delineate the associations between exposures to b-lactam antibiotics and VRE colonization, we tested a variety of b-lactam antibiotics in the mouse establishment model. MATERIALS AND METHODS Bacterial strain. We used E. faecium strain C68, an ampicillinand vancomycin-resistant (VanB-type) clinical strain. This strain has been extensively described in the past and is the strain used in our previous animal studies [12, 14]. Microbiologic techniques. Broth macrodilution MICs were performed in brain-heart infusion broth. Overnight cultures grown without antibiotic selection were diluted to achieve an inoculum of 10 5 cfu/ml. Cultures were incubated overnight at 37 C, and the MIC was determined to be that in the tube containing the lowest concentration of antibiotic for which there was no detectable turbidity after 24 h of incubation. Standard 2-fold dilutions of antibiotics were used. Mouse model. The mouse model of VRE colonization was essentially the same as that described in our previous study [14], with a few modifications. In brief, g female CF1 mice (Harlan Sprague-Dawley) were administered subcutaneous (sc) injections of antibiotics 2 times per day for 2 days before gavage of organisms and for the duration of the experiment. These antibiotics were chosen on the basis of differing concentrations in the biliary tract and differing activities against anaerobic bacteria. Except for piperacillin-tazobactam, none exhibited significant in vitro activity against ampicillin-resistant E. faecium. The characteristics of the different test antibiotics are shown in table 1. The dose of antibiotics chosen reflected the usual daily dose for a 70-kg human, adjusted for the weight of the mouse, and was divided into 2 doses administered 12 h apart. The choice of administration frequency does not reflect either human or mouse pharmacokinetics of the antibiotics. It was chosen to make antimicrobial administration more practical and to minimize repeated injections for the mice over the 9 days of the study. Total daily doses of each antibiotic administered to the mice were the following: aztreonam (3 mg/ 1114 JID 2004:189 (15 March) Rice et al.
3 Table 1. Characteristics of antimicrobial agents. Antibiotic Class/generation Activity against ampicillin-resistant Enterococcus faecium Biliary concentration (multiple of serum concentration) Antianaerobic activity Aztreonam Monobactam None 1 None Cefazolin Cephalosporin/first None 3 Weak Cefepime Cephalosporin/fourth None 2 Weak Cefotetan Cephalosporin/second, cephamycin None Potent Ceftazidime Cephalosporin/third, antipseudomonal None 0.2 Weak Ceftriaxone Cephalosporin/third None Modest Piperacillin-tazobactam Ureidopenicillin-inhibitor combination Modest 5 10 Potent NOTE. These data are derived from previous studies [15, 17 20]. day), cefazolin (3 mg/day), cefepime (3 mg/day), cefotetan (2 mg/day), ceftazidime (3 mg/day), ceftriaxone (1 mg/day), and piperacillin-tazobactam (6.75 mg/day). Control mice were administered a volume of saline equivalent to that used in the administration of antibiotics. After 2 days of sc administration of antibiotics, mice were administered an inoculum of cfu of E. faecium C68, derived by saline dilutions of a frozen stock of known inoculum, by use of a stainless steel feeding tube (Perfektum; Popper & Sons). Fresh stool samples were obtained from all mice on days 1, 3, and 6 after gavage. Stool samples were weighed, homogenized in sterile saline, and serially diluted. Dilutions were plated onto Enterococcosel agar containing vancomycin (6 mg/ml). Colonies that hydrolyzed esculin in the agar were counted after 48 h of incubation. When no VRE were detectable on initial screening, a larger aliquot (100 ml) was plated, to increase detection of small numbers of VRE (lower limit of detection, 2.0 log 10 cfu/g); if no VRE were detected from these samples, a number equal to the lower limit of detection was assigned. In a deviation from the previous protocol, in the first 2 series of experiments, the bedding in the cages was not changed on a regular basis. This increased the risk that coprophagia (the act of mice ingesting their own stool) would lead to ingestion of continuous inocula of VRE. To determine whether this difference in protocol had an effect on our results, we performed additional experiments in which ceftazidime, piperacillin-tazobactam, ceftriaxone, or saline was administered in doses equivalent to those in the earlier experiments, but with daily changes in the cage bedding. Results of these experiments are reported separately. In this set of experiments, stool samples were obtained on days 1, 3, 6, and 9. These experiments were reviewed and approved by the Louis Stokes Cleveland VA Medical Center Animal Care and Use Committee. Statistical analysis. Statistical analyses were performed by use of STATA software (version 5.0; StataCorp). Log 10 colonyforming units were determined across the 3 data-collection time points for individual mice. These were then examined by use of a 1-way analysis of variance, by antibiotic treatment. Overall differences and pair-wise differences were examined, with P values adjusted for multiple comparisons by use of the Scheffe correction. RESULTS Establishing VRE colonization. Log 10 colony-forming units per gram of stool for the initial experiments are shown in figure 1. Consistent with previous experiments, ceftriaxone promoted colonization at high levels very quickly, with extensive colonization demonstrable by day 1 after inoculation of organisms. The numbers of VRE colony-forming units found in the stool of ceftriaxone-treated mice decreased over time, which also is consistent with previous experiments. We interpret this decrease as reflecting the relatively modest activity of ceftriaxone against anaerobic bacteria minimizing the persistence of high levels of VRE colonization, as observed in previous experiments using the VRE persistence model [12]. Cefotetan also promoted colonization at high levels, and these levels persisted over time. It is noteworthy that cefotetan, like ceftriaxone, is highly concentrated in the bile and, as such, may be particularly likely to promote the establishment of colonization. Moreover, its potent activity against anaerobic bacteria will promote persistence of high levels of colonization. It is similar in its antibacterial activity to ticarcillin-clavulanic acid, which also promotes establishment and persistence of VRE colonization in this and other models [12, 14]. In contrast to the results for ceftriaxone and cefotetan, there was no tendency to promote colonization on the part of aztreonam, cefazolin, or cefepime. Administration of these antibiotics was statistically equivalent to administration of saline. As detailed in table 1, these antimicrobial agents are neither concentrated in the bile nor potent in their activity against anaerobic bacteria. In this setting, their lack of activity against ampicillin-resistant E. faecium may well become irrelevant, since they are present in concentrations too low to provide a significant selective advantage for enterococcal proliferation. Results obtained in mice treated with either ceftazidime or b-lactam Antibiotics and VRE Colonization JID 2004:189 (15 March) 1115
4 Figure 1. Bar graph demonstrating log 10 cfu of Enterococcus faecium C68 per gram of feces, 1, 3, and 6 days after inoculation of 200 cfu of E. faecium C68 into the stomach of mice pretreated with the indicated antimicrobial agents. Results represent the 2 experiments in which cage bedding was not changed on a daily basis. Lines extending above the bars represent the SD for the log 10 cfu per gram of feces. Means of the 3 determinations were examined by use of a 1-way analysis of variance, by antibiotic treatment. Overall differences and pair-wise differences were examined, with P values adjusted for multiple comparisons by use of the Scheffe correction. *Difference is significant, vs. all other groups except ceftriaxone. Difference is significant, vs. all other groups except cefotetan and piperacillin-tazobactam. Difference is significant, vs. normal saline, aztreonam, and cefazolin. piperacillin-tazobactam were more complex. In the first experimental group treated with ceftazidime, it appeared that this antibiotic significantly promoted colonization with VRE. The second experiment, however, suggested only minimal promotion of colonization (data not shown). For the piperacillin-tazobactam treated mice, results on day 1 were consistent with those of previous experiments, showing no significant promotion of VRE colonization. However, results obtained on days 3 and 6 of these experiments were at odds with those of the previous experiments, in that they indicated an association of administration of piperacillin-tazobactam with increasing quantities of fecal VRE over time. Review of the current and previous protocols revealed 2 potential explanations for this difference. First, the doses of piperacillin-tazobactam administered to the mice in the present study were slightly lower than those administered in previous studies (6.75 vs. 8 mg/day). Second, in contrast to the investigators in previous experiments [14], we did not regularly change cage bedding. As such, it was possible that, in the mice, continued ingestion of colonized feces could have resulted in a persistent exposure to increasing inocula of VRE. Preliminary experiments with a small number of mice suggested that daily bedding changes would prevent the association of piperacillin-tazobactam with colonization over time (data not shown). We therefore performed a third set of experiments, with ceftazidime (8 mice), piperacillin-tazobactam (8 mice), ceftriaxone (2 mice), or saline (2 mice), in which we made certain that bedding was changed on a daily basis, in an attempt to minimize the contribution of coprophagia to our results. The results of these experiments are presented in figure 2. VRE colonization was virtually undetectable in all 8 piperacillin-tazobactam treated mice. Overall, levels of colonization for piperacillin-tazobactam treated mice were comparable to those for mice administered saline, which is similar to the result of our previous study [14]. Ceftazidimetreated mice exhibited variable levels of colonization. Overall, these levels of colonization were statistically greater than those for piperacillin-tazobactam treated mice and less than those for ceftriaxone-treated mice but were not different from those for mice that were administered saline alone. These data are consistent with a contribution of coprophagia to the discrepancies between the results of piperacillin-tazobactam treatment in these experiments and those that we reported previously. DISCUSSION The data presented here suggest that one strategy to avoid promoting gastrointestinal VRE colonization is to select antimicrobial agents with minimal biliary excretion. Previously published data suggest that neither aztreonam, cefazolin, cefepime, nor ceftazidime is significantly concentrated in human bile after normal dosing [18 20]. Also, these agents do not have potent activity against anaerobic bacteria. If these data on mice can be applied to humans, it would, therefore, seem that aztreonam, cefazolin, and cefepime could probably be used for the infections for which they are indicated without significant concern about promoting gastrointestinal VRE colonization. These data are particularly reassuring for cefazolin, given the frequency with which this antibiotic is used for surgical pro JID 2004:189 (15 March) Rice et al.
5 Figure 2. Bar graph demonstrating log 10 cfu of Enterococcus faecium C68 per gram of feces, 1, 3, 6, and 9 days after inoculation of 200 cfu of E. faecium C68 into the stomach of mice pretreated with the indicated antimicrobial agents. The nos. of mice in each group were as follows: saline, 2; ceftazidime, 8; piperacillin-tazobactam, 8; and ceftriaxone, 2. Results represent the single experiment in which cage bedding was changed daily. Lines extending above the bars represent the SD for the log 10 cfu per gram of feces. P!.05, ceftriaxone vs. normal saline, ceftazidime, and piperacillin-tazobactam. P!.05, ceftazidime vs. piperacillintazobactam. phylaxis, and for cefepime, which is used frequently in immunocompromised patients. Our results indicate that the effect of ceftazidime in our model is less predictable. Of note, ceftazidime has been specifically implicated in human gastrointestinal VRE colonization in at least 1 study [21]. Among antimicrobial agents that achieve significant gastrointestinal concentrations, our results suggest that piperacillintazobactam exerts an inhibitory effect against VRE colonization. However, this inhibition is not absolute, since persistent exposure to VRE inocula in mice treated with piperacillintazobactam results in high-level colonization with VRE over time. It should be acknowledged that our choice of dosing 2 times per day could put piperacillin-tazobactam at a disadvantage in the face of persistent and possibly increasing exposures to VRE. In humans, piperacillin-tazobactam is usually administered 4 or 6 times per day, which could increase its protective effect against VRE colonization by yielding biliary concentrations that are more consistently elevated than would be likely with dosing 2 times per day in mice. We are not aware of data from clinical studies linking exposure to piperacillintazobactam with increased risk of VRE colonization or infection, despite the fact that its potency against anaerobic bacteria is significant. The lack of clinical data associating piperacillintazobactam with VRE supports the hypothesis that the activity of this combination in the upper gastrointestinal tract is usually enough to inhibit high-level VRE colonization in humans. Our data serve to emphasize the importance of infection control measures for control of VRE in the hospital, since the quantities of VRE in the stool samples of mice subjected to repeated inocula were higher than observed when repeated inocula were not present, even in mice that were administered normal saline. The repeated observation that high-level VRE colonization cannot be established to a significant extent in the absence of antibiotic administration should also be emphasized and used to promote judicious and parsimonious use of antibiotics in all settings. Finally, our data suggest that all cephalosporins are not alike in their tendency to promote VRE colonization and that the tendency to promote colonization can be predicted on the basis of their intrinsic characteristics (biliary excretion, activity against enterococci, and anaerobic bacteria). When assessing the risk of colonization or infection with VRE, future clinical studies should try, as much as possible, to distinguish between exposure to different types of cephalosporins. References 1. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database USA. Clin Infect Dis 1999; 29: Murdoch DR, Mirrett S, Harrell LJ, Monahan JS, Reller LB. Sequential emergence of antibiotic resistance in enterococcal bloodstream isolates over 25 years. Antimicrob Agents Chemother 2002; 46: Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance System. Available at: hip/surveill/nnis.htm. Accessed 19 February Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46: Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135: Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21: Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34: Baldassarri L, Bertuccini L, Ammendolia MG, Gherardi G, Creti R. Variant esp gene in vancomycin-sensitive Enterococcus faecium. Lancet 2001; 357: Rice LB, Carias L, Rudin S, et al. A potential virulence gene, hyl Efm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 2003; 187: Bonten MJM, Slaughter S, Ambergen AW, et al. The role of colonization pressure in the spread of vancomycin-resistant enterococci. Arch Intern Med 1998; 158: Puzniak LA, Mayfield J, Leet T, Kollef M, Mundy LM. Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis 2001; 33: Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 1999; 180: Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343: Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 2000; 181: Taylor EW, Poxon V, Alexander-Williams J, Jackson D. Biliary excretion of piperacillin. J Int Med Res 1983; 11: b-lactam Antibiotics and VRE Colonization JID 2004:189 (15 March) 1117
6 16. Donskey CJ, Schreiber JR, Jacobs MR, et al. A polyclonal outbreak of predominantly VanB vancomycin resistant enterococci in northeast Ohio. Clin Infect Dis 1999; 29: Hayton WL, Schandlik R, Stoeckel K. Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy. Eur J Clin Pharmacol 1986; 30: Martinez OV, Levi JU, Devlin RG. Biliary excretion of aztreonam in patients with biliary tract disease. Antimicrob Agents Chemother 1984; 25: McLeish AR, Strachan CJ, Powis SJ, Wise R, Bevan PG. The influence of biliary disease on the excretion of cefazolin in human bile. Surgery 1977; 81: Okamoto MP, Gill MA, Nakahiro RK, et al. Tissue concentrations of cefepime in acute cholecystitis patients. Ther Drug Monit 1992; 14: Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999; 43: JID 2004:189 (15 March) Rice et al.
Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationEffect of Antibiotic Treatment on Establishment and Elimination of Intestinal Colonization by KPC-Producing Klebsiella pneumoniae in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2011, p. 2585 2589 Vol. 55, No. 6 0066-4804/11/$12.00 doi:10.1128/aac.00891-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Effect
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationEmergence of Vancomycin-Resistant Enterococci
Emergence of Vancomycin-Resistant Enterococci Louis B. Rice VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA Vancomycin and ampicillin resistance in clinical
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD
Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationVisit ABLE on the Web at:
This article reprinted from: Lessem, P. B. 2008. The antibiotic resistance phenomenon: Use of minimal inhibitory concentration (MIC) determination for inquiry based experimentation. Pages 357-362, in Tested
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationThe Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED
JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi:10.1128/jcm.00801-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationTitle: Effect of fidaxomicin versus vancomycin on susceptibility to intestinal
AAC Accepted Manuscript Posted Online 18 April 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.02590-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 Title: Effect of
More informationMulticenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2417 2422 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Multicenter Study of In Vitro
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Enterococcal Species
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 44 Enterococcal Species Authors Jacob Pierce, MD, Michael Edmond, MD, MPH, MPA Michael P. Stevens, MD, MPH Chapter Editor Victor D. Rosenthal, MD, CIC,
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationMeasurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist
Measurement of Antimicrobial Drug Use Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Defined Daily Dose Target Audience: Administrators and Epidemiologists Standardized definition
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationSAMPLE. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals
VET01 5th Edition Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals This standard covers the current recommended methods for disk diffusion
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationEpidemiology and Microbiology of Surgical Wound Infections
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 918 922 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Epidemiology and Microbiology of Surgical
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationVancomycin-resistant Enterococcus: Risk factors, surveillance, infections, and treatment
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2008 Vancomycin-resistant Enterococcus: Risk factors, surveillance, infections, and treatment John E. Mazuski Washington
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationFecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin
ISPUB.COM The Internet Journal of Infectious Diseases Volume 2 Number 2 Fecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin E Nahum, Z Samra, J Ben-Ari, O Dagan,
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationExtremely Drug-resistant organisms: Synergy Testing
Extremely Drug-resistant organisms: Synergy Testing Background Acinetobacter baumannii& Pseudomonas aeruginosa Emerging Gram-negative bacilli Part of the ESKAPE group of organisms 1 Enterococcus faecium
More informationProject Summary. Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms
Project Summary Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms Principal Investigators: Mindy Brashears, Ph.D., Texas Tech University Guy
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationSELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle
SELECT NEWS Florfenicol Monograph: Injectable Therapy for Cattle Did you know that? Florfenicol is one of the most powerful antibiotics currently available in veterinary medicine with one of the lowest
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationResearch Article Risk Factors Associated with Vancomycin-Resistant Enterococcus in Intensive Care Unit Settings in Saudi Arabia
Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 369674, 4 pages http://dx.doi.org/10.1155/2013/369674 Research Article Risk Factors Associated with Vancomycin-Resistant Enterococcus
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationMolecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis
Journal of Antimicrobial Chemotherapy (2004) 53, 626 630 DOI: 10.1093/jac/dkh138 Advance Access publication 18 February 2004 Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis
More informationMultiple drug resistance pattern in Urinary Tract Infection patients in Aligarh
Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh Author(s): Asad U Khan and Mohd S Zaman Vol. 17, No. 3 (2006-09 - 2006-12) Biomedical Research 2006; 17 (3): 179-181 Asad
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More information